Besides, our study may provide new therapeutic targets for PCa patients and the underlying mechanisms for them (MAGI2-AS3-SPARC/GJA1/CYSLTR1, DLG5-AS1-DEFB1, and RHPN1-AS1-CDC45/ORC). This evidence concerns the gene MAGI2 and posterior cortical atrophy.